Robotic Radiotherapy Market Precision on the Rise Expanding Treatment Options 2024-2031

Head and Neck Cancer Market worth $ 9.07 Billion by 2030 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Head and Neck Cancer Market- by Products (Cytotoxic Agents, Antimetabolites, Abitrexate/Mexate/Folex (methotrexate), Hydrea (hydroxyurea), Antitubulins, Taxotere (docetaxel), Others (Platinum Agents, Fluoropyrimidines), Platinol (cisplatin), 5-fluorouracil

(5-FU), EGFR Inhibitors (mAbs), Erbitux (cetuximab), Vectibix (panitumumab), Theracim/Theraloc (nimotuzumab), EGFR Inhibitors (TKIs), Tarceva (erlotinib), Iressa (gefitinib), Tykerb/Tyverb (lapatinib), PD1 Inhibitors, Keytruda (pembrolizumab), Opdivo (nivolumab), Pipeline Drugs (Late-stage), EGFR Inhibitors (mAbs), Vectibix (panitumumab), PDL1 Inhibitors, Imfinzi (durvalumab), Bavencio (avelumab), CTLA4 Inhibitors, Yervoy (ipilimumab) and Tremelimumab), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

Get a free sample copy of the report: https://www.insightaceanalytic.com/request-sample/1217

According to the latest research by InsightAce Analytic, the global Head and Neck Cancer market is valued at US$ 2.44 Billion in 2021, and it is expected to reach US$ 9.07 Billion by 2030, with a CAGR of 16.2% during a forecast period of 2024-2031.

Head and Neck Cancer: An Overview
Head and neck cancers (HNC) are a group of malignancies that develop in the squamous cells lining the mucosal surfaces of the head and neck region, including the inside of the mouth, nose, and throat. HNC can also affect the salivary glands, pharynx, paranasal sinuses, and oral cavity.

It is a significant global health concern, ranking as the sixth most common cancer worldwide with approximately 630,000 new cases diagnosed annually. Squamous cell carcinomas are the most prevalent type of HNC, affecting not only the head and neck but also the oral cavity, scalp, and paranasal sinuses. The oral cavity is the most common site for HNC development, with a strong link to tobacco and alcohol use.

Market Drivers
The head and neck cancer market is experiencing growth due to several factors:
• Rising HNC Incidence: The primary driver of the market is the increasing number of head and neck cancer cases globally.

• Aging Population: As the global population ages, the risk of HNC increases, further fueling market demand.

• Increased Government Support: Growing government backing for HNC research and treatment initiatives is a positive factor.

• Enhanced Market Competition: Heightened competition in the HNC treatment market is leading to innovation and potentially more effective treatments.

• Focus on Oncology Research: Significant funding directed towards oncology research holds promise for the development of new and improved HNC treatments.

• Unmet Medical Needs: The existence of unmet medical needs in HNC treatment creates opportunities for novel therapies.

• Strengthened Regulatory Framework: A more robust regulatory framework can ensure the safety and efficacy of new HNC treatments.

Challenges and Considerations
Despite these growth drivers, the head and neck cancer market faces some

challenges:
• High Treatment Costs: The high cost of HNC treatment can be a barrier for some patients, hindering market growth.

• Treatment Limitations: Current treatment options for HNC have limitations, necessitating the development of more effective therapies.

• Limited Healthcare Access: The lack of universal healthcare and inadequate healthcare systems in some regions restrict access to HNC treatment.

• Clinical Trial Challenges: The inefficiency of some drug development processes and the high rate of failed clinical trials pose an obstacle for the introduction of new HNC treatments.

Scientific and technological advancements in manufacturing processes and research have the potential to expedite the development of new and more effective HNC medications. However, the challenges associated with clinical trials require ongoing efforts to improve success rates and accelerate the delivery of innovative treatments to patients.

I hope this revision improves readability by separating the explanation of head and neck cancer from the market analysis and highlighting the specific factors driving growth and challenges.

North America is anticipated to be the major contributor to the Head and Neck Cancer market over the forecast years due to the rising incidence of head and neck cancer, rising use of cutting-edge medical technologies, large market player presence, high healthcare costs, and increased knowledge of contemporary cancer treatments.

In addition, the Asia Pacific regional market is expected to register significant growth during the estimated period. The need for therapies for treating head and neck cancer is anticipated to increase due to the region's rapidly expanding patient population, which would likely propel the market. Manufacturers should benefit financially from expanding the biopharmaceutical sector and local government initiatives in the coming years.

Major market players operating in the Head and Neck Cancer market include
Advaxis, Inc. (US), Amgen, Inc. (US), AstraZeneca plc (UK), Boehringer Ingelheim GmbH (Germany), Bristol-Myers Squibb Company (Ono Pharmaceutical Co., Ltd.) (Japan), Cel-Sci Corporation (US), Five Prime Therapeutics, Inc. (US),

GlaxoSmithKline plc (UK), Incyte Corporation (US), IRX Therapeutics, Inc. (US), MacroGenics, Inc. (US), Merck KGaA (Germany), Novartis AG (Switzerland), Pfizer, Inc., Roche Holdings AG (Genentech) (Switzerland), Viracta Therapeutics (US) among others.

Recent collaborations and agreements in the market:
• In July 2021, Novartis (Switzerland) partnered with Kura Oncology, Inc., a clinical-stage biopharmaceutical company, to assess the efficacy of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma.


• In June 2021, CEL-SCI Corporation (United States) revealed the results of a 9.5-year pivotal Phase 3 research for its immunotherapy Multikine (Leukocyte Interleukin, Injection) in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN). In a significant head and neck cancer phase 3 study, CEL-Multikine® SCI's Immunotherapy achieved a 14.1% 5-year survival benefit (62.7% vs 48.6%) in the group undergoing surgery plus radiotherapy.

Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1217

Market Segments
Global Head and Neck Cancer Market, by Products, 2022-2030 (Value US$ Mn)
• Cytotoxic Agents
• Antimetabolites
• Abitrexate/ Mexate/ Folex (methotrexate)
• Hydrea (hydroxyurea)
• Antitubulins
• Taxotere (docetaxel)
• Others (Platinum Agents, Fluoropyrimidines)
• Platinol (cisplatin)
• 5-fluorouracil (5-FU)
• EGFR Inhibitors (mAbs)
• Erbitux (cetuximab)
• Vectibix (panitumumab)
• Theracim/Theraloc (nimotuzumab)
• EGFR Inhibitors (TKIs)
• Tarceva (erlotinib)
• Iressa (gefitinib)
• Tykerb/Tyverb (lapatinib)
• PD1 Inhibitors
• Keytruda (pembrolizumab)
• Opdivo (nivolumab)
• Pipeline Drugs (Late-stage)
• EGFR Inhibitors (mAbs)
• Vectibix (panitumumab)
• PDL1 Inhibitors
• Imfinzi (durvalumab)
• Bavencio (avelumab)
• CTLA4 Inhibitors
• Yervoy (ipilimumab)
• Tremelimumab

Global Head and Neck Cancer Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America Head and Neck Cancer Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada

Europe Head and Neck Cancer Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific Head and Neck Cancer Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America Head and Neck Cancer Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa Head and Neck Cancer Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global Head and Neck Cancer market
 To receive an industry overview and future trends of the Head and Neck Cancer market
 To analyze the Head and Neck Cancer market drivers and challenges
 To get information on the Head and Neck Cancer market value (US$ Mn) forecast to 2030
 Significant investments, mergers & acquisitions in the Head and Neck

Cancer market industry
For More Information @ https://www.insightaceanalytic.com/customisation/1217

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions.
Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.
We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.
Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.